AMAPCEO and OPSEU pressed the OPS Employer to expand benefits coverage of GLP-1 and semaglutide medications. On the pharma front, Novo took the first round of the oral obesity duel ahead of Lilly. Separately, Medical Daily outlined a case of four months of gut distress on semaglutide, where a biopsy found immune cells where they should not be. Medscape noted no clear link could be seen between semaglutide and depression. Korea Biomedical Review reported that a regulator verified no causal tie in reported Mounjaro pancreatitis cases.